Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Current Obesity Reports Springer Nature Link CagriSema vs Tirzepatide: 23% Weight Loss in Phase 3 Trial Recent advances in peptide based therapies for obesity and type 2 diabetes ScienceDirect cagrisema #tirzepatide #cagrilintide #semaglutide #obesity #weightloss #redefine4 Martin Haluzk Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination Semaglutide vs Tirzepatide, Cagrilintide, and Retatrutide: Mechanisms & Research Insights